Welcome Guest | Register / Login

Pharmaceuticals Market Research Reports

The global pharmaceutical market has persistently experienced significant growth due to the ever-increasing demand for novel and more effective drugs. The reasons for this steady increase in the demand for drugs worldwide can be attributed to population growth, newer and more complex disease conditions, ageing population, and the increased prevalence of chronic and infectious diseases, some of which still remain incurable and fatal. Such numerous unmet needs and high demand rates have triggered the boost in R&D investments by key industry sectors, greatly driving the growth of this i... View more

Sort By
Title Published Price Buy Now
United States Influenza Vaccine Market, Vaccination Analysis, Distribution, Production, Pipeline Insights, Clinical Trials, Deals Type, Regulatory, Price Trends, Competitive Strategies and Forecast,2016 to 2022
By DPI Research
United States Influenza Vaccine Market is expected to reach more than US$ 2.5 Billion by the year end of 2022. Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and adv...
Dec 2016 $ 1000
United States Pharmaceuticals and Healthcare Report Q1 2017
By Business Monitor International
BMI View: The surprise victory of Donald Trump in the US presidential election provides something of a mixed bag for multinational drugmakers' revenue-earning opportunities in the country. Indeed, while potentially lower medicine expendit...
Nov 2016 $ 1295
Saudi Arabia Pharmaceuticals and Healthcare Report Q1 2017
By Business Monitor International
BMI View: Although issues pertaining to market access will continue to be of concern for multinational drugmakers, the Saudi Arabian pharmaceutical market will remain as one of the most commercially attractive in the Middle East and Afric...
Nov 2016 $ 1295
Romania Pharmaceuticals and Healthcare Report Q1 2017
By Business Monitor International
BMI View: In line with Romania's economic outperformance in Europe, the country's pharmaceutical and healthcare markets will see strong growth given increased consumer spending power and higher healthcare contributions. However, aggressiv...
Nov 2016 $ 1295
Poland Pharmaceuticals and Healthcare Report Q1 2017
By Business Monitor International
BMI View: The outlook for both Poland's pharmaceutical and healthcare markets will be driven by government reforms targeting greater access to healthcare. Over the short term, changes to reimbursement and co-payment exemptions will boost ...
Nov 2016 $ 1295
Philippines Pharmaceuticals and Healthcare Report Q1 2017
By Business Monitor International
BMI View: Despite high enrolment numbers with the Philippine Health Insurance Corporation (PhilHealth), further reforms to the Philippines's healthcare system will be necessary for the country's universal healthcare scheme to galvanise th...
Nov 2016 $ 1295
Mauritius Pharmaceuticals and Healthcare Report Q1 2017
By Business Monitor International
BMI View: Healthcare spending growth and a business-friendly policy environment will continue to create commercial opportunities for drugmakers and healthcare operators in Mauritius over the forecast period. Meanwhile, the outlook for a s...
Nov 2016 $ 1295
Lebanon Pharmaceuticals and Healthcare Report Q1 2017
By Business Monitor International
BMI View: The ongoing Syrian civil war has had a substantial impact on Lebanon's healthcare service and finances, with a troubled political climate further exacerbating the crisis. On a positive note, the influx of international funds to ...
Nov 2016 $ 1295
Jordan Pharmaceuticals and Healthcare Report Q1 2017
By Business Monitor International
BMI View: Growth within Jordan's pharmaceutical market will be supported by a growing network of trade agreements and entry into new export markets. As a fall in domestic demand prompts expansion strategies, Jordanian drugmakers will cont...
Nov 2016 $ 1295
Italy Pharmaceuticals and Healthcare Report Q1 2017
By Business Monitor International
BMI View: The rising demand for medicines for the treatment of cardiovascular diseases, gastric conditions, the nervous system and the respiratory system (the therapeutic areas that recorded the highest expenditure in 2015) and the govern...
Nov 2016 $ 1295
Israel Pharmaceuticals and Healthcare Report Q1 2017
By Business Monitor International
BMI View: Israel will continue to be targeted by multinational drugmakers as a destination for innovative drug sales; however, their relative success will be limited by funding constraints towards the country's health services basket and ...
Nov 2016 $ 1295
Iraq Pharmaceuticals and Healthcare Report Q1 2017
By Business Monitor International
BMI View: Despite an expected improvement in Iraq's economic activity over the coming quarters, political instability and security threats will limit the country's ability to attract pharmaceutical investors. Against this background, drug...
Nov 2016 $ 1295
Iran Pharmaceuticals and Healthcare Report Q1 2017
By Business Monitor International
BMI View: The removal of economic sanctions heralds an era of uncertainty for Iran's pharmaceutical market. Underlying issues regarding the operating environment will prevent an immediate uptick in multinational drugmaker interest; rather...
Nov 2016 $ 1295
Germany Pharmaceuticals and Healthcare Report Q1 2017
By Business Monitor International
BMI View: Despite the challenging drug reimbursement environment, Germany's large and growing pharmaceutical market will remain among the most attractive worldwide to pharmaceutical investors over the coming years. Key growth drivers such...
Nov 2016 $ 1295
Costa Rica Pharmaceuticals and Healthcare Report Q1 2017
By Business Monitor International
BMI View: Costa Rica is, and will continue to be, one of the most attractive pharmaceutical markets in the Central America region. Although regulatory and patent enforcement concerns remain, steps are being taken to address these shortfal...
Nov 2016 $ 1295
Venezuela Pharmaceuticals and Healthcare Report Q1 2017
By Business Monitor International
BMI View: The activity of multinational pharmaceutical companies in Venezuela will remain limited over the coming quarters. Venezuela's economic crisis has had a direct impact on healthcare spending, as outof- pocket spending is a primary...
Nov 2016 $ 1295
Slovakia Pharmaceuticals and Healthcare Report Q1 2017
By Business Monitor International
BMI View: Slovakia's pharmaceutical market represents an opportunity for revenue growth for multinational drugmakers. The advanced regulatory environment will enable robust growth within the patented medicines market and the country will ...
Nov 2016 $ 1295
Russia Pharmaceuticals and Healthcare Report Q1 2017
By Business Monitor International
BMI View: Russia's healthcare market is in a precarious position due to a severe lack of funding and an escalating burden of disease. Amendments to Russia's pharmaceutical legislation will favour domesticallyproduced medicines over foreig...
Nov 2016 $ 1295
Pakistan Pharmaceuticals and Healthcare Report Q1 2017
By Business Monitor International
BMI View: The development of Pakistan's pharmaceutical sector will remain stymied as uncertainty over the country's pricing regime causes firms to withhold further investments. We do not expect this to improve over the coming quarters as ...
Nov 2016 $ 1295
Oman Pharmaceuticals and Healthcare Report Q1 2017
By Business Monitor International
BMI View: Oman's evolving demographic and epidemiological profile will act as key drivers of growth within the country's pharmaceuticals and healthcare markets over the coming years - shaping opportunities for multinational pharmaceutical...
Nov 2016 $ 1295
New Zealand Pharmaceuticals and Healthcare Report Q1 2017
By Business Monitor International
BMI View: Multinational drugmakers seeking to commercialise their innovative treatments in New Zealand will continue to face challenges from the Pharmaceutical Management Agency. While the agency has played a pivotal role in ensuring the ...
Nov 2016 $ 1295
Namibia Pharmaceuticals and Healthcare Report Q1 2017
By Business Monitor International
BMI View: While Namibia's business environment is conducive to foreign direct investment (FDI), the country's relatively small pharmaceutical market and below-average per capita spending on medicines lowers its competitiveness in the Sout...
Nov 2016 $ 1295
Mozambique Pharmaceuticals and Healthcare Report Q1 2017
By Business Monitor International
BMI View: The Mozambican government's commitment to restructuring its debt burden as a result of pressure from the country's creditors following the debt scandal will lead to implementation of spending cuts across various sectors includin...
Nov 2016 $ 1295
Moldova Pharmaceuticals and Healthcare Report Q1 2017
By Business Monitor International
BMI View: Moldova's pharmaceutical market presents very limited opportunities for multinational drugmakers, in comparison to its neighbours in Eastern Europe. The country's small total market size and its reliance on out-of-pocket payment...
Nov 2016 $ 1295
Ireland Pharmaceuticals and Healthcare Report Q1 2017
By Business Monitor International
BMI View: A significant increase in Ireland's 2017 health budget will support the increasing demand for medical treatment. However, cost control measures targeting pharmaceutical spending and the relatively small drug market will continue...
Nov 2016 $ 1295